866-997-4948(US-Canada Toll Free)

Skin Cancer Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Nov 2012

Category :

Cancer

No. of Pages : 282 Pages


Global Markets Directs, \'Skin Cancer Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Skin Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Cancer. 

Skin Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Skin Cancer.
  • A review of the Skin Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Skin Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Skin Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Skin Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 11
Introduction 12
Global Markets Direct Report Coverage 12
Skin Cancer Overview 13
Therapeutics Development 14
An Overview of Pipeline Products for Skin Cancer 14
Skin Cancer Therapeutics under Development by Companies 16
Skin Cancer Therapeutics under Investigation by Universities/Institutes 28
Late Stage Products 36
Comparative Analysis 36
Mid Clinical Stage Products 37
Comparative Analysis 37
Early Clinical Stage Products 38
Comparative Analysis 38
Discovery and Pre-Clinical Stage Products 39
Comparative Analysis 39
Skin Cancer Therapeutics Products under Development by Companies 40
Skin Cancer Therapeutics Products under Investigation by Universities/Institutes 52
Companies Involved in Skin Cancer Therapeutics Development 67
Bristol-Myers Squibb Company 67
Johnson & Johnson 68
F. Hoffmann-La Roche Ltd. 69
Vical Incorporated 70
Amgen Inc. 71
Adherex Technologies Inc. 72
AstraZeneca PLC 73
Eli Lilly and Company 74
Viralytics Ltd. 75
GlaxoSmithKline plc 76
Nektar Therapeutics 77
Antigenics, Inc. 78
Inovio Biomedical Corporation 79
Merck & Co., Inc. 80
Lentigen Corporation 81
Oxford BioMedica plc 82
Generex Biotechnology Corporation 83
Plexxikon Inc. 84
Delcath Systems, Inc. 85
Amorfix Life Sciences Ltd. 86
Piramal Healthcare Limited 87
Innocell Corporation 132
Scancell Holdings Plc 133
MabVax Therapeutics, Inc. 134
Antigen Express, Inc. 135
Digna Biotech, S.L. 136
Oryzon 137
PCI Biotech Holding ASA 138
Antisense Pharma GmbH 139
Bionucleon Srl 140
Ambit Biosciences Corporation 141
Philogen S.p.A. 142
Hutchison MediPharma Limited 143
Telormedix SA 144
Hawthorn Pharmaceuticals, Inc. 145
MacroGenics, Inc. 146
Boston Biomedical, Inc. 147
PDS Biotechnology Corporation 148
AlphaVax, Inc. 149
Azaya Therapeutics, Inc. 150
Iconic Therapeutics, Inc. 151
ProNAi Therapeutics, Inc. 152
Jennerex Biotherapeutics, Inc. 153
Axelar AB 154
Pharminox Limited 155
Immutep S.A. 156
Innogene Kalbiotech Pte Ltd. 157
Intrexon Corporation 158
NovaLead Pharma Pvt. Ltd. 159
Welichem Biotech Inc. 160
Vaccinogen, Inc. 161
Oncolys BioPharma Inc. 162
APEIRON Biologics AG 163
TSD Japan, Inc. 164
Immunocore Limited. 165
Immune Design Inc. 166
NewLink Genetics Corporation 167
SBI Biotech Co., Ltd. 168
InteRNA Technologies B.V. 169
Avir Green Hills Biotechnology AG 170
TVAX Biomedical, LLC 171
AmpliMed Corporation 172
Cannabis Science, Inc. 173
Genelux Corporation 174
WntResearch AB 175
Viventia Biotechnologies Inc. 176
Lytix Biopharma AS 177
Medisyn Technologies, Inc. 178
Moberg Derma AB 179
ImmuneRegen BioSciences, Inc. 180
AIMM Therapeutics B.V. 181
Cancer Therapeutics CRC Pty Ltd 182
Targa Therapeutics Corp. 183
ImmunoFrontier, Inc. 184
Bioo Therapeutics 185
Pacific Northwest Biotechnology, LLC 186
Polaris Group 187
EyeGene, Inc. 188
IkerChem S.L. 189
ToleroTech Inc. 190
ISA Pharmaceuticals B.V. 191
Gradalis Inc. 192
SentoClone AB 193
Advancell 194
Skin Cancer Therapeutics Assessment 195
Assessment by Monotherapy Products 195
Assessment by Combination Products 196
Assessment by Route of Administration 197
Assessment by Molecule Type 199
Drug Profiles 201
nilotinib - Drug Profile 201
vismodegib - Drug Profile 203
talminogene laherparepvec - Drug Profile 205
Aldesleukin + Recombinant Interferon Alfa + Cisplatin + Dacarbazine + Vinblastine - Drug Profile 207
Proleukin + Maxamine - Drug Profile 209
sirolimus - Drug Profile 211
interferon alfa-2b - Drug Profile 212
GSK-2132231-A - Drug Profile 213
API-31510 - Drug Profile 214
Carboplatin + Paclitaxel + Sorafenib - Drug Profile 216
interferon alfa-2b - Drug Profile 217
Aldesleukin + Filgrastim + Recombinant Interferon Alfa + Cisplatin + Dacarbazine + Vinblastine - Drug Profile 218
bevacizumab - Drug Profile 220
GSK2118436 + GSK1120212 - Drug Profile 221
GM2-KLH Vaccine + QS21 Adjuvant - Drug Profile 223
ipilimumab - Drug Profile 225
lomustine - Drug Profile 226
peginterferon alfa-2b - Drug Profile 227
Tumor Infiltrating Lymphocytes + Interleukin 2 - Drug Profile 228
ranibizumab - Drug Profile 229
cholecalciferol - Drug Profile 230
Dacarbazine + Fotemustine - Drug Profile 231
Dacarbazine + Fotemustine + Interferon Alfa-2b - Drug Profile 232
POL-103A - Drug Profile 233
Skin Cancer Therapeutics Drug Profile Updates 235
Skin Cancer Therapeutics Discontinued Products 243
Skin Cancer Therapeutics - Dormant Products 246
Skin Cancer Product Development Milestones 271
Featured News & Press Releases 271

Appendix 279
Methodology 279
Coverage 279
Secondary Research 279
Primary Research 279
Expert Panel Validation 279
Contact Us 280
Disclaimer 280

List of Table


Number of Products Under Development for Skin Cancer, H2 2012 16
Products under Development for Skin Cancer Comparative Analysis, H2 2012 17
Number of Products under Development by Companies, H2 2012 19
Number of Products under Development by Companies, H2 2012 (Contd..1) 20
Number of Products under Development by Companies, H2 2012 (Contd..2) 21
Number of Products under Development by Companies, H2 2012 (Contd..3) 22
Number of Products under Development by Companies, H2 2012 (Contd..4) 23
Number of Products under Development by Companies, H2 2012 (Contd..5) 24
Number of Products under Development by Companies, H2 2012 (Contd..6) 25
Number of Products under Development by Companies, H2 2012 (Contd..7) 26
Number of Products under Development by Companies, H2 2012 (Contd..8) 27
Number of Products under Development by Companies, H2 2012 (Contd..9) 28
Number of Products under Development by Companies, H2 2012 (Contd..10) 29
Number of Products under Investigation by Universities/Institutes, H2 2012 31
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 32
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 33
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 34
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 37
Comparative Analysis by Late Stage Development, H2 2012 38
Comparative Analysis by Mid Clinical Stage Development, H2 2012 39
Comparative Analysis by Early Clinical Stage Development, H2 2012 40
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 41
Products under Development by Companies, H2 2012 42
Products under Development by Companies, H2 2012 (Contd..1) 43
Products under Development by Companies, H2 2012 (Contd..2) 44
Products under Development by Companies, H2 2012 (Contd..3) 45
Products under Development by Companies, H2 2012 (Contd..4) 46
Products under Development by Companies, H2 2012 (Contd..5) 47
Products under Development by Companies, H2 2012 (Contd..6) 48
Products under Development by Companies, H2 2012 (Contd..7) 49
Products under Development by Companies, H2 2012 (Contd..8) 50
Products under Development by Companies, H2 2012 (Contd..9) 51
Products under Development by Companies, H2 2012 (Contd..10) 52
Products under Development by Companies, H2 2012 (Contd..11) 53
Products under Investigation by Universities/Institutes, H2 2012 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 64
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 65
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 67
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 68
Bristol-Myers Squibb Company, H2 2012 69
Johnson & Johnson, H2 2012 70
F. Hoffmann-La Roche Ltd., H2 2012 71
Vical Incorporated, H2 2012 72
Amgen Inc., H2 2012 73
Adherex Technologies Inc., H2 2012 74
AstraZeneca PLC, H2 2012 75
Eli Lilly and Company, H2 2012 76
Viralytics Ltd., H2 2012 77
GlaxoSmithKline plc, H2 2012 78
Nektar Therapeutics, H2 2012 79
Antigenics, Inc., H2 2012 80
Inovio Biomedical Corporation, H2 2012 81
Merck & Co., Inc., H2 2012 82
Lentigen Corporation, H2 2012 83
Oxford BioMedica plc, H2 2012 84
Generex Biotechnology Corporation, H2 2012 85
Plexxikon Inc., H2 2012 86
Delcath Systems, Inc., H2 2012 87
Amorfix Life Sciences Ltd., H2 2012 88
Piramal Healthcare Limited, H2 2012 89
Prolexys Pharmaceuticals, Inc., H2 2012 90
Aposense Ltd., H2 2012 91
Biofrontera AG, H2 2012 92
Histogen, Inc., H2 2012 93
ZIOPHARM Oncology, Inc., H2 2012 94
Millennium Pharmaceuticals, Inc., H2 2012 95
Novartis AG, H2 2012 96
Aphios Corporation, H2 2012 97
Ichor Medical Systems, Inc., H2 2012 98
Astellas Pharma Inc., H2 2012 99
Daewoong Pharmaceutical Co., Ltd., H2 2012 100
Eisai Co., Ltd., H2 2012 101
LEO Pharma A/S, H2 2012 102
Ono Pharmaceutical Co., Ltd., H2 2012 103
SuperGen, Inc., H2 2012 104
Takara Holdings Inc., H2 2012 105
Teva Pharmaceutical Industries Limited, H2 2012 106
Hadasit Medical Research Services & Development Ltd, H2 2012 107
Exelixis, Inc., H2 2012 108
Aduro BioTech, H2 2012 109
Alfacell Corporation, H2 2012 110
Bayer AG, H2 2012 111
MannKind Corporation, H2 2012 112
4SC AG, H2 2012 113
EpiCept Corporation, H2 2012 114
Hana Biosciences, Inc., H2 2012 115
Celldex Therapeutics, Inc., H2 2012 116
Anavex Life Sciences Corp., H2 2012 117
AEterna Zentaris Inc., H2 2012 118
Lorus Therapeutics Inc, H2 2012 119
Marshall Edwards, Inc., H2 2012 120
Cleveland BioLabs, Inc., H2 2012 121
Oncolytics Biotech Inc., H2 2012 122
Oncothyreon Inc, H2 2012 123
Compugen Ltd., H2 2012 124
Patrys Limited, H2 2012 125
Curis, Inc., H2 2012 126
CytoGenix, Inc., H2 2012 127
La Jolla Pharmaceutical Company, H2 2012 128
BTG International Ltd, H2 2012 129

List of Chart


Number of Products under Development for Skin Cancer, H2 2012 16
Products under Development for Skin Cancer Comparative Analysis, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 30
Late Stage Products, H2 2012 38
Mid Clinical Stage Products, H2 2012 39
Early Clinical Stage Products, H2 2012 40
Discovery and Pre-Clinical Stage Products, H2 2012 41
Assessment by Monotherapy Products, H2 2012 197
Assessment by Combination Products, H2 2012 198
Assessment by Route of Administration, H2 2012 199
Assessment by Stage and Route of Administration, H2 2012 200
Assessment by Molecule Type, H2 2012 201
Assessment by Stage and Molecule Type, H2 2012 202

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *